ETF Holdings Breakdown of CGEM

Stock NameCullinan Oncology LLC
TickerCGEM(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS2300311063

News associated with CGEM

Tower Research Capital LLC TRC Grows Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)
Tower Research Capital LLC TRC grew its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 411.3% during the 4th quarter, HoldingsChannel reports. The fund owned 8,800 shares of the company’s stock after buying an additional 7,079 shares during the period. Tower Research Capital LLC TRC’s holdings in Cullinan Therapeutics were worth […] - 2025-05-09 08:55:00
Wells Fargo & Company MN Acquires 8,056 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)
Wells Fargo & Company MN lifted its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 47.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,864 shares of the company’s stock after acquiring an additional 8,056 […] - 2025-05-07 07:24:54
Barclays PLC Sells 3,383 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)
Barclays PLC lowered its holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 1.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 245,231 shares of the company’s stock after selling 3,383 shares during the period. Barclays PLC’s holdings in Cullinan […] - 2025-04-30 08:50:47
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Legal & General Group Plc
Legal & General Group Plc decreased its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 7.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 42,808 shares of the company’s stock after selling 3,649 shares during the quarter. Legal & General Group Plc’s holdings in Cullinan Therapeutics were worth $521,000 as of […] - 2025-04-30 07:52:47
Brokerages Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) PT at $34.80
Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) has been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the […] - 2025-04-30 05:34:45
23,500 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by ExodusPoint Capital Management LP
ExodusPoint Capital Management LP bought a new stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 23,500 shares of the company’s stock, valued at approximately $286,000. Other hedge funds and other institutional investors also recently made changes […] - 2025-04-14 08:05:19
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Holdings Raised by American Century Companies Inc.
American Century Companies Inc. raised its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) by 11.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 100,721 shares of the company’s stock after buying an additional 10,010 shares during the period. American Century Companies Inc.’s holdings in Cullinan Therapeutics were worth […] - 2025-04-11 07:37:03
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)
Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,153 shares of the company’s stock, valued at approximately $136,000. Other large investors have […] - 2025-01-31 09:37:08
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Expected to Rise, HC Wainwright Analyst Says
Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) had its price objective boosted by investment analysts at HC Wainwright from $28.00 to $33.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 200.55% from the stock’s […] - 2025-01-31 08:38:56

CGEM institutional holdings

The following institutional investment holdings of CGEM have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 26,020USD 202,175
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 16,729USD 129,984
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 28,658USD 222,673
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 28,658USD 222,673 0.9%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 249USD 1,935
Total =100,314 USD 779,440
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.